Aditya Bardia
Program Director, Breast Medical Oncology & Assistant Chief, Translational Research, Hematology/Oncology Division UCLA Health
Dr. Aditya Bardia is an internationally renowned breast oncologist known for his pioneering clinical and translational research in the field of cancer therapeutics, particularly antibody drug conjugates. He is the principal investigator of several clinical trials investigating precision therapeutics, and he has led the clinical development of novel therapies, including sacituzumab govitecan (IMMU-132), the first ADC approved for patients with metastatic TNBC, elacestrant, the first oral SERD approved for patients with metastatic HR+ breast cancer. Dr. Bardia led the clinical development of blood-based biomarkers, such as CTCs and ctDNA, as “liquid biopsy” for identification of novel targets, therapy selection, monitoring, and understanding resistance to guide therapeutic development.
Seminars
- Contextualizing ADC clinical class effect toxicities to understand barriers to progression to standard of care and early-stage therapies
- Explaining the physician’s perspective and patient attitudes to ADC treatments given anti-tumor efficacy and associated toxicity profiles
- Breaking down clinical toxicity mitigation strategies: What are the top learnings to pass back to ADC developers?
